Researchers developed a CRISPR and single-molecule microarray test that quantifies Candida auris and detects antifungal resistance in under 40 minutes. The assay provides rapid, precise results from ...
Australian scientists have used AI to design molecules that make gene editing technology safer, potentially revolutionising ...
Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...
Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
If I were to locate the moment AI slop broke through into popular consciousness, I’d pick the video of rabbits bouncing on a ...
The rapid spread of animal diseases and pathogen evolution have long posed significant threats to the healthy development of ...
VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...
Picture CRISPR-Cas9, a gene editing technology, as a GPS-guided scalpel: gRNA directs the Cas9 enzyme, a protein that cuts ...
Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...
A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act like molecular anchors. The work confirms these tags actively silence genes, ...
When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) stock declines while market improves: Some information for investors
In the latest close session, CRISPR Therapeutics AG (CRSP) was down 8.7% at $55.52. The stock fell short of the S&P 500, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results